Vaxon
Closed: January 2019
What did we did for the company
- Financial, legal and commercial DD on their acquisition target.
- looking at £30m investment from Vaxon Biotech, a French Cancer Vaccine company.
Company details
- VAXON Biotech develops innovative therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using its proprietary technology of optimized cryptic peptides.
- Vaxon Biotech’s therapeutic vaccines are intended to treat existing cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. VAXON’s vaccines utilize proprietary optimized cryptic peptides and target universal tumor antigens that are highly overexpressed in a wide range of tumors while being present in very low quantities in normal tissues.